References
- Berk M, Fitzsimons J, Lambert T . Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs 2007; 21:117–127.
- Cowan C, Oakley C. Leukopenia and neutropenia induced by quetiapine. ProgNeuropsychopharmacol Biol Psychiatry 2007; 31:292–294.
- Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine. Psychosomatics 2001; 42:368.
- Shankar BR. Quetiapine-induced leucopenia and thrombo cytopenia. Psychosomatics 2007; 48:530–531.
- Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002–2007. Aust N Z J Psychiatry 2010; 44:372–377.
- Watts RG. Neutropenia. Lee GR FJ, Foerster J, Lukens J ., Wintrobe’s Clinical Hematology. 10th. Baltimore: Lippincott, Williams & Wilkins, 1999:1862–1888.
- Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7:S17–25.
- Claas FH. Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacology (Berl) 1989; 99:S113–117.
- Mason RP, Fischer V. Possible role of free radical formation in drug-induced agranulocytosis. Drug Saf 1992; 7:S45–50.
- Uetrecht JP. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf 1992; 7:S51–56.
- King DJ, Quetiapine: Results of four phase II and III clinical trials. Eur Psychiatry 1998; 13:S15–21.